VIPoma syndrome: challenges in management

Adam, N. and Lim, S.S. and Ananda, V. and Chan, S.P. (2010) VIPoma syndrome: challenges in management. Singapore Medical Journal, 51 (7). e129-32. ISSN 0037-5675, DOI 20730389.

Full text not available from this repository.
Official URL:


Vasoactive intestinal peptide-producing tumour (VIPoma) or Verner-Morrison syndrome is a very rare neuroendocrine tumour. It occurs in less than ten percent of all pancreatic islet cell tumours, and about 70 percent to 80 percent of these tumours originate from the pancreas. Diagnosis is characteristically delayed. The first-line treatment is surgical. It may be curative in forty percent of patients with benign and non-metastatic disease. Palliative surgery is indicated in extensive disease, followed by conventional somatostatin analogue (octreotide) therapy. Somatostatin analogues improve hormone-mediated symptoms, reduce tumour bulk and prevent local and systemic effects. We present a female patient with VIPoma syndrome, which had metastasised to the liver at diagnosis. The patient underwent palliative Whipple procedure and subsequent cytoreductive radiofrequency ablations to her liver metastases. Unfortunately, after symptomatic improvement for three years, her disease progressed. Currently, she is on daily octreotide, achieving partial control of her symptoms.

Item Type: Article
Additional Information: Endocrine Unit, Department of Medicine, University of Malaya, Lembah Pantai, Kuala Lumpur 50603, Malaysia.
Uncontrolled Keywords: Catheter Ablation/methods; Combined Modality Therapy
Subjects: R Medicine
Divisions: Faculty of Medicine
Depositing User: Mr. Faizal Hamzah
Date Deposited: 19 May 2011 02:33
Last Modified: 14 Jan 2019 01:22

Actions (login required)

View Item View Item